1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,870 | 1,980 | 13:04 | |
| 1,830 | 1,940 | 10.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ASCLETIS PHARMA Aktie jetzt für 0€ handeln | |||||
| Di | Ascletis Pharma-B Selects ASC30_39 FDC for Clinical Development | 1 | AASTOCKS | ||
| Di | Ascletis Pharma Inc.: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development | 72 | PR Newswire | -Fixed-dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in their respective... ► Artikel lesen | |
| Di | ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES FIXED-DOSE COMBINATION OF ASC30, ONCE-DAILY ORAL SMALL MOLECULE GLP-1R AGONIST, AND ASC39, ... | 1 | HKEx | ||
| 31.03. | ASCLETIS-B (01672): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND CHANGE IN THE USE OF PROCEEDS | 1 | HKEx | ||
| 18.03. | ASCLETIS-B (01672): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 17.03. | ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ORAL SMALL MOLECULE AMYLIN RECEPTOR AGONIST ASC39 DEMONSTRATED ELORALINTIDE-LIKE AMYLIN SELECTIVITY AND EFFICACY ... | 1 | HKEx | ||
| 10.03. | Ascletis eyes quarterly GLP-1 dosing following phase 2 obesity readout | 1 | FierceBiotech | ||
| 10.03. | Ascletis Pharma Inc.: Ascletis Announces Positive Topline Results from U.S. Phase II, 24-Week Study for Its Ultra-Long-Acting Subcutaneous Depot Formulations of Small Molecule GLP-1R Agonist ASC30 for Obesity | 612 | PR Newswire | - ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of 7.5% at week 16... ► Artikel lesen | |
| 10.03. | ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM U.S. PHASE II, 24-WEEK STUDY FOR ITS ULTRA-LONG-ACTING SUBCUTANEOUS ... | 1 | HKEx | ||
| 11.02. | ASCLETIS-B (01672): VOLUNTARY ANNOUNCEMENT - ASCLETIS SELECTS ORAL AMYLIN RECEPTOR PEPTIDE AGONIST, ASC36, FOR CLINICAL DEVELOPMENT | 2 | HKEx | ||
| 10.02. | ASCLETIS-B (01672): NEXT DAY DISCLOSURE RETURN | 4 | HKEx | ||
| 10.02. | ASCLETIS-B (01672): COMPLETION OF PLACING OF NEW SHARES UNDER THE GENERAL MANDATE | 1 | HKEx | ||
| 06.02. | Ascletis Pharma Inc.: GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China's Core Innovative Drug Assets | 491 | JCN Newswire | HONG KONG, Feb 6, 2026 - (ACN Newswire) - According to disclosure of interests filed with the Hong Kong Stock Exchange (HKEX), the Government of Singapore Investment Corporation (GIC) has acquired an... ► Artikel lesen | |
| 06.02. | Ascletis Pharma Inc.: GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share | 379 | JCN Newswire | HONG KONG, Feb 6, 2026 - (ACN Newswire) - According to the disclosure of interests information released by the Hong Kong Stock Exchange, on 5 February, GIC Private Limited made its first equity investment... ► Artikel lesen | |
| 05.02. | Ascletis Pharma Inc.: GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share | 243 | JCN Newswire | HONG KONG, Feb 5, 2026 - (ACN Newswire) - According to the disclosure of interests information released by the Hong Kong Stock Exchange, GIC Private Limited made its equity investment in Ascletis Pharma... ► Artikel lesen | |
| 05.02. | Sagimet announces positive results for Ascletis' denifanstat in moderate to severe acne | 8 | PMLiVE | ||
| 03.02. | ASCLETIS-B (01672): PLACING OF NEW SHARES UNDER THE GENERAL MANDATE | 5 | HKEx | ||
| 02.02. | Ascletis reports positive long-term safety data for acne drug denifanstat | 4 | Investing.com | ||
| 02.02. | Sagimet Biosciences Inc.: Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne | 342 | GlobeNewswire (Europe) | SAN MATEO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic... ► Artikel lesen | |
| 29.01. | Ascletis Pharma Inc.: Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne | 322 | PR Newswire | - Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study
-... ► Artikel lesen |
1 2 3 4 Weiter >>
68 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 81,40 | -0,06 % | BioNTech vs. Bioxyne: Wenn Forschungs-Riesen pausieren und Small Caps die Prognosen anheben | ||
| EVOTEC | 4,530 | +0,09 % | Aktien KW 15 Trump hält die Börsen im Griff. Wacklige Waffenruhe bringt Erholung, aber… News. Mutares. Evotec. TKMS. technotrans. HENSOLDT. Renk. Circus. Albis Leasing. Rheinmetall | Aktien - Erholungsaufatmer nach Waffenstillstand. Mit apokalyptischen Drohungen malte Trump die "Steinzeit" für den Iran an die Wand. Unter Vermittlung Pakistans - auch Chinas? - gab es kurz vorher... ► Artikel lesen | |
| BB BIOTECH | 48,350 | 0,00 % | Dividenden als Portfolio-Anker: Alte Bekannte Sanofi und BB Biotech - Geheimtipp RE Royalties | In einem Marktumfeld, das von strukturellen Umbrüchen geprägt ist, rückt die Stabilität des Portfolios in den Fokus. Analysten von J.P. Morgan betonen, dass der Schutz von Buchgewinnen der vergangenen... ► Artikel lesen | |
| MEDIGENE | 0,025 | -18,83 % | Medigene: Zurückziehung - 18.11.2025 | ||
| QIAGEN | 35,045 | +0,04 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MODERNA | 43,330 | -0,30 % | Moderna, Inc.: Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 | CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010... ► Artikel lesen | |
| PAION | 0,051 | -19,84 % | XFRA MISTRADE ANTRAG IN ISIN DE000A3E5EG5 WURDE STATTGEGEBEN | Dem Mistrade-Antrag wurde stattgegeben. Folgende Geschaefte in der ISIN DE000A3E5EG5, Wertpapier-Name: PAION AG INH O.N., wurden aufgehoben:ISIN Datum Zeit Volumen PreisDE000A3E5EG5 02.02.2026 08:13:40 300 0... ► Artikel lesen | |
| VALNEVA | 2,668 | -1,11 % | Valneva mit Rekordsignal: Was große Adressen zum Wochenstart bereits wissen - Was erfahrene Anleger jetzt analysieren | ||
| AMGEN | 299,00 | -0,10 % | Amgen: Phase 3 Trial Of TEPEZZA Meets Primary And Key Secondary Endpoints | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced positive topline results from a Phase 3 trial of TEPEZZA administered by subcutaneous injection via an on-body injector in participants with... ► Artikel lesen | |
| EPIGENOMICS | 0,920 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 6,860 | -1,01 % | Activist investor revives campaign to overhaul Novavax board | ||
| STRYKER | 289,50 | +0,10 % | Stryker confident of 2026 outlook despite Q1 impact from cyberattack | ||
| BIOGEN | 147,04 | -0,28 % | Biogen to acquire Apellis in $5.6bn deal | ||
| BIOFRONTERA | 2,610 | +2,35 % | BIOFRONTERA AG im Abwärtsmodus - ruhige Einordnung | ||
| HEIDELBERG PHARMA | 2,810 | +3,31 % | EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest | EQS-Ad-hoc: Heidelberg Pharma AG / Schlagwort(e): Sonstiges
Heidelberg Pharma AG: Heidelberg Pharma legt Dosis für Phase II-Studie (RP2D) mit dem ADC-Kandidaten HDP-101 fest
09.04.2026... ► Artikel lesen |
ASCLETIS PHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,040 (+2,12 %) liegt der Kurs bei 1,930 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCLETIS PHARMA INC finden Sie auf Wallstreet Online.